PL3003386T3 - Koniugaty przeciwciało lek - Google Patents

Koniugaty przeciwciało lek

Info

Publication number
PL3003386T3
PL3003386T3 PL14732514T PL14732514T PL3003386T3 PL 3003386 T3 PL3003386 T3 PL 3003386T3 PL 14732514 T PL14732514 T PL 14732514T PL 14732514 T PL14732514 T PL 14732514T PL 3003386 T3 PL3003386 T3 PL 3003386T3
Authority
PL
Poland
Prior art keywords
conjugatates
antibody drug
antibody
drug
conjugatates antibody
Prior art date
Application number
PL14732514T
Other languages
English (en)
Inventor
Cármen CUEVAS MARCHANTE
Juan Manuel DOMÍNGUEZ CORREA
Andrés FRANCESCH SOLLOSO
María GARRANZO GARCÍA-IBARROLA
María José MUNOZ ALONSO
Francisco SÁNCHEZ MADRID
Juan Manuel ZAPATA HERNÁNDEZ
Alicia García Arroyo
Maria Ángeles URSA PECHARROMÁN
Original Assignee
Pharma Mar S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar S.A. filed Critical Pharma Mar S.A.
Publication of PL3003386T3 publication Critical patent/PL3003386T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
PL14732514T 2013-05-31 2014-06-02 Koniugaty przeciwciało lek PL3003386T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1309807.4A GB201309807D0 (en) 2013-05-31 2013-05-31 Antibody drug conjugates
PCT/EP2014/061392 WO2014191578A1 (en) 2013-05-31 2014-06-02 Antibody drug conjugates
EP14732514.6A EP3003386B1 (en) 2013-05-31 2014-06-02 Antibody drug conjugates

Publications (1)

Publication Number Publication Date
PL3003386T3 true PL3003386T3 (pl) 2020-04-30

Family

ID=48805601

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14732514T PL3003386T3 (pl) 2013-05-31 2014-06-02 Koniugaty przeciwciało lek

Country Status (31)

Country Link
US (2) US11224663B2 (pl)
EP (1) EP3003386B1 (pl)
JP (1) JP6412114B2 (pl)
KR (2) KR102340681B1 (pl)
CN (1) CN105451775B (pl)
AR (2) AR096461A1 (pl)
AU (1) AU2014273052B2 (pl)
BR (1) BR112015029816B1 (pl)
CA (1) CA2914041C (pl)
CL (1) CL2015003481A1 (pl)
CY (1) CY1122662T1 (pl)
DK (1) DK3003386T3 (pl)
ES (1) ES2778045T3 (pl)
GB (1) GB201309807D0 (pl)
HR (1) HRP20200032T1 (pl)
IL (1) IL242571B (pl)
LT (1) LT3003386T (pl)
MX (1) MX356431B (pl)
MY (1) MY176579A (pl)
NZ (1) NZ715646A (pl)
PL (1) PL3003386T3 (pl)
PT (1) PT3003386T (pl)
PY (1) PY1422863A (pl)
RS (1) RS59855B1 (pl)
RU (1) RU2669812C2 (pl)
SG (1) SG11201509563UA (pl)
SI (1) SI3003386T1 (pl)
SM (1) SMT202000023T1 (pl)
UA (1) UA119327C2 (pl)
WO (1) WO2014191578A1 (pl)
ZA (1) ZA201508487B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170058043A1 (en) * 2014-12-06 2017-03-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
MX2018001507A (es) * 2015-08-03 2018-09-18 Enb Therapeutics Llc Composiciones y metodos para tratar cánceres asociados con la activacion del etbr.
MA45280B1 (fr) 2016-03-02 2021-08-31 Eisai R&D Man Co Ltd Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
WO2018075308A1 (en) * 2016-10-17 2018-04-26 Princeton Enduring Biotech, Inc. Long acting multi-specific molecules and related methods
EP3381474A1 (en) * 2017-03-27 2018-10-03 Alfasigma S.p.A. Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
US11332480B2 (en) 2017-04-27 2022-05-17 Pharma Mar, S.A. Antitumoral compounds
WO2019099374A2 (en) * 2017-11-14 2019-05-23 University Of Virginia Patent Foundation Compositions and methods for making and using bispecific antibodies
BR112020010503A2 (pt) * 2017-11-30 2020-10-20 Seattle Genetics, Inc. processo para a preparação de compostos ligantes a fármacos
CN111465399A (zh) * 2017-12-01 2020-07-28 艾伯维公司 抗cd40抗体药物结合物
IL275757B2 (en) 2018-01-08 2025-08-01 Regeneron Pharma Steroids and antibody-conjugates thereof
CA3117145A1 (en) * 2018-10-21 2020-04-30 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CN118027137A (zh) 2018-12-21 2024-05-14 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
US20220226496A1 (en) * 2019-05-02 2022-07-21 Legochem Biosciences, Inc. Ligand-drug conjugate including linker having tris structure
CN113727734A (zh) * 2019-05-02 2021-11-30 乐高化学生物科学股份有限公司 包含具有tris结构的连接子的配体-药物偶联物
CA3139809A1 (en) * 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
EP3760233B1 (en) 2019-05-20 2023-07-12 MabPlex International Co., Ltd. One-pot preparation process for antibody drug conjugate intermediate
US20220265845A1 (en) * 2019-07-31 2022-08-25 Advanced Biodesign Aminothiolester compounds and uses thereof
CA3175426A1 (en) * 2020-04-21 2021-10-28 Alfonso Latorre Lozano Drug antibody conjugates
CN114262377B (zh) * 2021-10-28 2024-03-22 新疆优迈生物技术有限公司 一种阻断cd70与其配体cd27结合的抗人cd70纳米抗体的制备方法及其编码序列
CN115873066A (zh) * 2022-07-27 2023-03-31 吉林省博大伟业制药有限公司 一种抗体偶联药物连接子的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
DK1594542T3 (da) * 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
ATE522514T1 (de) * 2006-06-16 2011-09-15 Pharma Mar Sa Dihydropyran-2-onverbindungen mit antitumorwirkung
BRPI0821116B8 (pt) * 2007-12-20 2021-05-25 Pharma Mar Sa composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
AU2009248993C1 (en) 2008-05-23 2013-10-03 Wyeth Llc Triazine compounds as PI3 kinase and mTOR inhibitors
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2010149688A2 (en) * 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds

Also Published As

Publication number Publication date
MX2015016417A (es) 2016-07-05
AR123672A2 (es) 2023-01-04
WO2014191578A1 (en) 2014-12-04
RU2015156499A (ru) 2017-06-30
LT3003386T (lt) 2020-01-27
KR20160030132A (ko) 2016-03-16
RU2015156499A3 (pl) 2018-03-27
CY1122662T1 (el) 2021-03-12
US12410148B2 (en) 2025-09-09
KR102448393B1 (ko) 2022-09-28
RS59855B1 (sr) 2020-02-28
CA2914041A1 (en) 2014-12-04
BR112015029816B1 (pt) 2022-10-04
RU2669812C2 (ru) 2018-10-16
AU2014273052B2 (en) 2018-03-08
ZA201508487B (en) 2017-11-29
PY1422863A (es) 2017-09-01
CN105451775A (zh) 2016-03-30
EP3003386A1 (en) 2016-04-13
US20220168436A1 (en) 2022-06-02
CL2015003481A1 (es) 2016-08-19
US20160129128A1 (en) 2016-05-12
BR112015029816A2 (pt) 2017-07-25
KR20210156848A (ko) 2021-12-27
NZ715646A (en) 2019-05-31
SMT202000023T1 (it) 2020-03-13
PT3003386T (pt) 2020-01-21
UA119327C2 (uk) 2019-06-10
AU2014273052A1 (en) 2016-01-28
CA2914041C (en) 2021-12-07
MX356431B (es) 2018-05-29
KR102340681B1 (ko) 2021-12-20
SG11201509563UA (en) 2015-12-30
ES2778045T3 (es) 2020-08-07
MY176579A (en) 2020-08-17
JP2016526042A (ja) 2016-09-01
HRP20200032T1 (hr) 2020-03-20
US11224663B2 (en) 2022-01-18
IL242571B (en) 2019-10-31
CN105451775B (zh) 2019-09-06
SI3003386T1 (sl) 2020-03-31
GB201309807D0 (en) 2013-07-17
AR096461A1 (es) 2015-12-30
EP3003386B1 (en) 2019-10-16
JP6412114B2 (ja) 2018-10-24
DK3003386T3 (da) 2020-01-27

Similar Documents

Publication Publication Date Title
FR25C1038I1 (fr) Conjugue anticorps anti-trop2-medicament
IL281485B (en) Tracked all-terrain vehicle
DK3736291T5 (da) Anti-FCRH5-antistoffer
DK3049441T3 (da) Anti-PDL1-antistofformuleringer
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
CL2015003481A1 (es) Conjugados de anticuerpo fármaco
EP3083682C0 (en) DOUBLE SPECIFICITY ANTIBODIES
DK2970389T3 (da) Farmaceutiske forbindelser
DK3041857T3 (da) Protein a-kromatografi
DK3068800T3 (da) FcRn-specifikke antistoffer
UY4325S (es) Otomana
HRP20190085T1 (hr) Anti-cd52 protutijela
DK3065774T3 (da) Anti-CCL17-antistoffer
EP2980573A4 (en) BIOSENSOR
LT3079667T (lt) Farmacinės vaisto formos
DK3003401T3 (da) Farmaceutisk præparat
DK3087177T3 (da) Antistofproduktion ex vivo
HRP20171888T1 (hr) Farmaceutski pripravci
DK2972363T3 (da) Immunpotenserende nanobærerlægemiddel
TH1401006962A (th) แอนติ-ทรานสกลูตามิเนส 2 แอนติบอดี
ES1096431Y (es) Dosificador de Medicamentos
UA26239S (uk) Пробка
TH1501000527B (th) จุกอุดรู
UA25504S (uk) Пробка
UA25143S (uk) Пробка